BN104 Granted Orphan Drug Designation by US FDA for the Treatment of Acute Myeloid Leukemia

BioNova Pharmaceuticals Limited (BioNova), a company
dedicated to the discovery, development and commercialization of innovative medicines for the
treatment of diseases with unmet medical needs, today announced that the U.S. Food and
Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to BN104 for the
treatment of acute myeloid leukemia (AML).